Start here if you're new
what it is
Syndax sells cancer drugs and is trying to turn a clinical-stage story into a real oncology business.
how it gets paid
FY2025 consolidated revenue was $172.4M (Revuforj net sales + Niktimvo collaboration revenue + ~$5.1M milestone/license/royalty).
why it's growing
Total revenue scaled from a small 2024 commercial base to $172.4M in 2025 as both launches contributed — the open question is how fast sales can outrun ~$400M guided 2026 R&D + SG&A (ex ~$50M non-cash stock comp).
what just happened
Q4 2025 revenue was $68.7M; the company reported a Q4 net loss of ~$68.0M (~$(0.78)/share) and FY2025 net loss of ~$285.4M (~$(3.29)/share) per its FY2025 results release.
At a glance
B balance sheet — gets the job done, barely
20/100 earnings predictability — expect surprises
Q4 2025 revenue $68.7M · net loss ~$68.0M
FY2025 net loss ~$(3.29)/share on $172.4M revenue
~$394M cash & investments at YE 2025
xvary composite: 61/100 — average
What they do
Syndax sells cancer drugs and is trying to turn a clinical-stage story into a real oncology business.
Syndax is not trying to outmuscle giant drug companies on size. It targets focused oncology settings where the right drug matters. On a consolidated basis, FY2025 revenue was $172.4M: $124.8M Revuforj net revenue, $42.4M Niktimvo collaboration revenue (Syndax’s share of profit on partner-reported Niktimvo net revenue of $151.6M), plus ~$5.1M milestone, license and royalty revenue.
How they make money
$172.4M
FY2025 consolidated revenue · two commercial products + collaboration economics
total revenue
$172.4M
commercial ramp
The products that matter
targets acute leukemia
Revuforj
$124.8M · ~72% of FY2025 consolidated revenue
this drug generated $124.8M in 2025 revenue and carries the commercial story right now.
largest revenue driver
treats chronic gvhd
Niktimvo
$42.4M collaboration rev · ~25% of FY2025 consolidated revenue
Syndax records 50% of Niktimvo net commercial profit; that came to $42.4M collaboration revenue in FY2025 on $151.6M partner-reported Niktimvo net revenue — a real second leg, with different accounting than Revuforj net sales.
second launch leg
Key numbers
$172.4M
FY2025 revenue
Consolidated top line per FY2025 results — Revuforj net sales plus Niktimvo profit-share collaboration revenue plus ~$5.1M other.
~$394M
cash & investments
Cash, cash equivalents and short-term investments at Dec 31, 2025 — management says this plus expected product/collaboration revenue can fund a path to profitability.
~$(3.29)
FY2025 EPS (GAAP)
Still deeply negative while commercializing — compare against ~$400M 2026 operating expense guidance.
15/100
stock stability
Stability score → how wild the stock has been → if your thesis needs a smooth ride, this chart has other plans.
Financial health
B
strength
- balance sheet grade B — adequate — nothing special
- risk rank 1 — safer than 95% of stocks
- price stability 15 / 100
- liquidity (reported) ~$394M cash & short-term investments · YE 2025
B — functional but not a standout on the balance sheet.
Total return vs. market
Return history isn't available for SNDX right now.
source: institutional data · return history unavailable
What just happened
FY2025 results
Q4 revenue $68.7M · FY revenue $172.4M — losses still large.
Per Syndax’s fourth quarter and full year 2025 release: Q4 total revenue included $44.2M Revuforj net revenue, $19.4M Niktimvo collaboration revenue, and $5.1M milestone, license and royalty revenue. FY2025 net loss was ~$285.4M (~$(3.29)/share); Q4 net loss ~$68.0M (~$(0.78)/share).
$68.7M
Q4 revenue
$(0.78)
Q4 EPS
$(3.29)
FY EPS
the number that mattered
The bridge from $172.4M revenue to profitability runs through operating leverage versus ~$400M guided 2026 R&D + SG&A (ex ~$50M stock comp) — that is the line to watch.
source: Syndax FY2025 results press release / Form 8-K (SEC), 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is commercial sales failing to outrun a $68M quarterly loss.
med
launch math still does not clear the burn
Syndax produced $68.7M in Q4 revenue and still posted a $68.0M net loss. That is not a broken launch. It is a reminder that scale has not arrived yet.
If quarterly revenue stalls near this level, dilution or more balance-sheet pressure stays on the table.
med
two products drive essentially the whole story
Revuforj contributed $124.8M net revenue; Niktimvo showed up as $42.4M collaboration revenue on $151.6M partner-reported product sales. Either launch stalling hits the whole narrative.
A slowdown in either launch hits 100% of the company narrative because there is no third engine here.
med
the stock already assumes the ramp is real
At roughly a $2B market cap on $172.4M of 2025 revenue, you are paying up for execution before profits exist. That can work. It also leaves less room for messy quarters.
When a money-loser misses, the multiple usually compresses before the business does.
Two drugs delivered $172.4M in 2025 revenue, but the company still lost $68M in Q4 alone. That gap is the whole risk case.
source: institutional data · regulatory filings · risk analysis
Pay attention to
metric
revenue versus loss in the next quarter
Q4 gave you $68.7M in revenue and a $68.0M net loss. That spread needs to improve. If it does not, the commercial ramp starts looking expensive instead of impressive.
calendar
next earnings report
Expected May 5, 2026. You want fresh evidence that both approved drugs are still adding revenue faster than operating costs are adding pain.
risk
Revuforj concentration
Revuforj contributed 72% of 2025 sales. That makes it the hero and the vulnerability at the same time.
trend
share-price behavior
The stock has traded between $9 and $25 over the last year and carries a 15/100 price stability score. If you own it, volatility is part of the product.
Analyst rankings
earnings predictability
20 / 100
in human-speak, analysts do not have a clean line of sight yet. Launch-stage biotech numbers still jump around.
risk rank
1
This screens safer than 95% of stocks on the provider's risk metric. That's a balance-sheet read, not a promise that the stock will feel calm.
source: institutional data
Institutional activity
institutional ownership data for SNDX is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$21
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive